The Biostatistics Shared Resource (BSR) is a core group of the UC Davis Comprehensive Cancer Center (UCDCCC). We support the research mission of the Cancer Center by providing expert consultation to investigators on the design, analysis, interpretation, and reporting of cancer-related studies. The BSR interacts broadly across the spectrum of research interests and partners from basic through translational, clinical and population cancer studies. Our group's biostatistics expertise spans the range necessary for this spectrum, including statistics for molecular biosciences, animal study design, clinical trials, community interventions, and large-scale administrative databases like the Cancer Registry. The BSR not only provides direct services but also serves as a clearinghouse, together with the Division of Biostatistics and the Clinical and Translational Science Center's biostatistics team, to leverage additional resources to meet the growing statistics needs of the UCDCCC, all six Cores, and all Shared Resources. We support the UCDCCC through all stages of research: we provide expert assistance with study design, statistical analysis, summary of findings, and presentation to the scientific community and the public. We interact with all Programs and all Shared Resources. We participate in the administration and management of Cancer Center research activities: the BSR director attends Senior Management meetings and is a reviewer and voting member of the Scientific Review committee for clinical research, and Dr. Qi participates in protocol review for all institutional clinical trials. We offer both formal teaching (podium courses, lectures, and workshops) and informal mentoring (serving as major professor, committee members, and training grant mentors) in biostatistics applications for medical research to cancer researchers. BSR members are innovators in biostatistical methods for cancer research. BSR members have contributed to new statistical methods for biomarker discovery, especially for high throughput assays (metabolomics, glycomics, miRNA). We also are leaders in the area of longitudinal studies of biological and functional change markers and in survival analysis and clinical trials. We adhere to best practices for reproducible research, including sharing of code and methods. Our support of the UCDCCC is highly efficient, leveraging institutional and CTSC support to extend the funding directly provided by the CCSG to provide free support for study design, pilot awards, and mentoring and training of new cancer researchers. Our recharge fees offer researchers a moderately priced alternative to other potential statistical services both within and outside the university.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA093373-14
Application #
9148400
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
14
Fiscal Year
2016
Total Cost
$204,792
Indirect Cost
$74,351
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529

Showing the most recent 10 out of 836 publications